03:28 AM EST, 11/08/2024 (MT Newswires) -- Dana Aftab, Chief Scientific Officer, Executive Vice President, Discovery and Translational Research, on November 05, 2024, sold 96,986 shares in Exelixis ( EXEL ) for $3,394,510. Following the Form 4 filing with the SEC, Aftab has control over a total of 504,780 shares of the company, with 498,945 shares held directly and 5,835 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/939767/000093976724000157/xslF345X05/wk-form4_1731026361.xml

Price: 33.11, Change: -1.01, Percent Change: -2.96